Solid Biosciences (SLDB) Shares Outstanding (Weighted Average) (2017 - 2026)

Solid Biosciences has disclosed Shares Outstanding (Weighted Average) across 10 years of filings, most recently posting $109.8 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $109.8 million, up 65.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $109.8 million (up 65.53% YoY), and the FY2025 annual result was $87.5 million, up 114.38% from the prior year.
• Shares Outstanding (Weighted Average) came in at $109.8 million for Q1 2026 at Solid Biosciences, up from $87.5 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $109.8 million in Q1 2026 to a low of $7.5 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $38.2 million (2024), against an average of $42.5 million.
• Across the five-year window, Shares Outstanding (Weighted Average) tumbled 93.3% in 2022 and soared 162.42% in 2023, its largest moves.
• Solid Biosciences' Shares Outstanding (Weighted Average) stood at $8.5 million in 2022, then jumped by 133.6% to $19.9 million in 2023, then jumped by 105.27% to $40.8 million in 2024, then jumped by 114.38% to $87.5 million in 2025, then grew by 25.49% to $109.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $109.8 million (Q1 2026), $87.5 million (Q4 2025), and $94.4 million (Q3 2025), per Business Quant data.